Healthcare business concept, Medical examination and growth graph data of business on tablet with doctor's health report clipboard on background.

BB Biotech

: BION

Market CapCHF3,291m

Last Close CHF59.4

BION, a Switzerland-based investment company, targets long-term capital growth from biotechnology companies developing and marketing innovative drugs. At least 90% of the portfolio is held in listed companies, primarily those that already have products on the market or promising drug candidates in advanced stages of development. BION is benchmarked against the Nasdaq Biotech index (in CHF) but managed on a bottom-up basis, with a focused c 20–35 stock portfolio.

More BB Biotech content >

Investment summary

According to BB Biotech’s (BION) investment team, the biotech industry has never looked in such a good position. Following a sell-off in the last 18 months, a combination of fundamental industry strength and discounted valuations has recently attracted investors to return to the biotech market. In the sector, BION is differentiated from the Nasdaq Biotechnology Index by its concentrated portfolio (c 30 stocks) of what the investment manager, Bellevue Asset Management, believes to be best-in-class biotech growth opportunities. The BION team continues to focus on its core portfolio of biotech staples, such as Moderna, blended with undiscovered, innovative companies, bringing new technologies.

Content on BB Biotech
BB Biotech – Great valuation potential
Investment companies | research Review | 13 September 2022
Healthcare business concept, Medical examination and growth graph data of business on tablet with doctor's health report clipboard on background.
BB Biotech – executive interview
Investment companies | Edison TV | 7 September 2022
BB Biotech – Looking for innovation beyond the pandemic
Investment companies | research Review | 1 March 2021
Healthcare business concept, Medical examination and growth graph data of business on tablet with doctor's health report clipboard on background.
View more
Register to receive research on BB Biotech as it is published
Sector
Investment companies
Access more Investment companies content
Share price graph
Price performance
%
1m
3m
12m
Actual 2.9 4.8 (24.5)
Relative* 0.2 2.2 (17.5)
52-week high/low CHF80.0/CHF51.0
*% relative to local index
Key management
Erich Hunziker Chairman
Claude Mikkelsen Director of IR
Daniel Koller Head of investment management
Dr Silvia Siegfried-Schanz Director of IR